Nautilus Advisors LLC Gilead Sciences, Inc. Transaction History
Nautilus Advisors LLC
- $136 Billion
- Q2 2025
A detailed history of Nautilus Advisors LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Nautilus Advisors LLC holds 7,157 shares of GILD stock, worth $838,657. This represents 0.58% of its overall portfolio holdings.
Number of Shares
7,157
Previous 7,157
-0.0%
Holding current value
$838,657
Previous $802 Million
1.05%
% of portfolio
0.58%
Previous 0.66%
Shares
2 transactions
Others Institutions Holding GILD
# of Institutions
2,330Shares Held
1.03BCall Options Held
12.1MPut Options Held
9.13M-
Black Rock Inc. New York, NY121MShares$14.1 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA119MShares$14 Billion0.22% of portfolio
-
State Street Corp Boston, MA59.2MShares$6.94 Billion0.25% of portfolio
-
Capital World Investors Los Angeles, CA46.3MShares$5.43 Billion0.78% of portfolio
-
Wellington Management Group LLP Boston, MA37.5MShares$4.4 Billion0.79% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $147B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...